Trailing Twelve Months Revenue Growth: Silexion Therapeutics Corp (SLXN)

Public company logo of Silexion Therapeutics Corp. (SLXN)

Silexion Therapeutics Corp (SLXN) operates in a stable environment, remaining shielded from trade conflicts. The company's success is based on the effectiveness of combating KRAS mutations in pancreatic cancer. This chart of trailing 12-month YoY revenue growth visualizes these processes, where 0.00 reflects the latest metric value. Structural flexibility is ensured by fully outsourcing production and clinical trials to third-party contractors.

Silexion Therapeutics (SLXN): Revenue Growth YoY (Last 12 Months) from 11/23/2025 to 11/19/2026

Silexion Therapeutics - analytical breakdowns and key metrics (SLXN)

- stock price and consensus target price:
- company stock exchange capitalization indicators:
Summary company analytics:silexion.com
Brand item of silexion.com

Revenue dynamics allow for an assessment of business resilience to market shocks, which is critical for Silexion Therapeutics Corp (SLXN) given its large-scale investments in AI-driven RNA modeling for tumor therapy. By analyzing the trailing twelve-month (TTM) sales growth, an investor can observe daily revenue changes over a 12-month period, providing an objective characterization of management efficiency, although sharp spikes in growth rates may signal that the asset is overbought.

Who Silexion Therapeutics Corp competes with

Incyte Pharma - Sales Growth YoY (Last Twelve Months)|HUTCHMED Corp - Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth Nuvation Bio Inc.|DAWN: Sales Growth YoY (TTM)|Revenue Growth Rate YoY (Last Twelve Months) Monopar Pharma MNPR|Revenue Growth YoY (Last 12 Months) INBX|Trailing Twelve Months Revenue Growth I-Mab Biopharma IMAB|Revenue Growth YoY (Last 12 Months) FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Revenue Dynamics YoY (Last Twelve Months)|Nuvectis Pharma, Inc. - Revenue Growth YoY (Last 12 Months)|Revenue Change YoY (Last 12 Months) CHRS (Coherus BioSciences)|Corbus Pharma - Sales Growth YoY (TTM)|Revenue Dynamics YoY (Last Twelve Months) CRDF (cardiffoncology.com)|BYSI: Sales Growth YoY (TTM)|Trailing Twelve Months Revenue Growth BioAtla Corp (BCAB)|Sales Growth YoY (Last Twelve Months) Lixte Biotechnology Holdings, Inc.|CTXR: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (TTM) CLRB|Sales Growth YoY (TTM) BioLineRx Corporation (BLRX)|Sales Growth YoY (Last Twelve Months) Can-Fite BioPharma, Ltd. CANF|APRE (aprea.com) - Trailing Twelve Months Sales Growth|KZIA: Revenue Growth YoY (Last 12 Months)|Trailing Twelve Months Revenue Growth NuCana|CMRX: Sales Growth YoY (TTM)|Revenue Growth YoY (Last 12 Months) Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Sales Growth YoY (TTM)|KRON: Revenue Dynamics YoY (Last Twelve Months)|Sales Growth YoY (Last Twelve Months) Kintara (KTRA)|Revenue Growth YoY (Last 12 Months) Oncternal ONCT|Portage Biotech - Revenue Growth YoY (Last 12 Months)